BGC Group, Inc. (Nasdaq: BGC) ("BGC" or "the Company") today announced the closing of the sale of kACE Financial ("kACE"), a ...
The analyses of progression-free survival (PFS) and overall survival (OS) remain on track for late Q1 2026 in the ongoing Phase 2/3 COMPANION-002 study of tovecimig (DLL4 x VEGF-A bispecific antibody) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback